Bridger Management’s Heron Therapeutics HRTX Stock Holding History

Bridger Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,721,816	Closed	-$40.5M	–	38
2019 Q4	$40.5M	Sell	1,721,816 -704,798	-29%	-$15.6M	2.92%	18
2019 Q3	$44.9M	Sell	2,426,614 -419,941	-15%	-$7.73M	3.71%	12
2019 Q2	$52.9M	Buy	2,846,555 +810,356	+40%	+$16.2M	4.15%	10
2019 Q1	$49.8M	Sell	2,036,199 -446,110	-18%	-$11.7M	3.94%	11
2018 Q4	$64.4M	Buy	2,482,309 +192,245	+8%	+$5.29M	5.37%	3
2018 Q3	$72.5M	Buy	2,290,064 +292,367	+15%	+$10.9M	4.19%	7
2018 Q2	$77.6M	Buy	1,997,697 +720,137	+56%	+$22.9M	4.2%	6
2018 Q1	$35.3M	Buy	+1,277,560	New	+$29M	2.14%	20

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bridger Management's HRTX Position: Q1 2020 in Review

Bridger Management sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 1,721,816 shares — an estimated $40.5M sold.

Bridger Management first reported a position in HRTX in Q1 2018 and held it in 8 quarters. The position peaked at $77.6M in Q2 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Bridger Management reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Bridger Management sold 1,721,816 Heron Therapeutics shares in Q1 2020, an estimated $40.5M.
Bridger Management first reported a position in Heron Therapeutics in Q1 2018 and held it in 8 quarters.
Bridger Management's Heron Therapeutics position peaked at $77.6M in Q2 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Bridger Management's 13F filing for Q1 2020, filed 15 May 2020.